{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:54:39Z","timestamp":1786395279755,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1 TR002535"],"award-info":[{"award-number":["1 TR002535"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jcf.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T15:20:14Z","timestamp":1621610414000},"page":"772-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Stacey L.","family":"Martiniano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-0103","authenticated-orcid":false,"given":"Brandie D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laney","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Wempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-4465","authenticated-orcid":false,"given":"Scott D.","family":"Sagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2021.04.011_bib0001","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1164\/rccm.200207-678OC","article-title":"Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis","volume":"167","author":"Olivier","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2021.04.011_bib0002","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3201\/eid1403.061405","article-title":"Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients","volume":"14","author":"Levy","year":"2008","journal-title":"Israel. Emerg Infect Dis."},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0003","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1055\/s-2007-995735","article-title":"Epidermoid accessory splenic cyst masquerading as a pancreatic mucinous cystic neoplasm","volume":"40","author":"Gleeson","year":"2008","journal-title":"Endoscopy"},{"issue":"7","key":"10.1016\/j.jcf.2021.04.011_bib0004","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1128\/JCM.43.7.3467-3470.2005","article-title":"Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis","volume":"43","author":"Pierre-Audigier","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.jcf.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3201\/eid0912.020774","article-title":"Mycobacterium abscessus and children with cystic fibrosis","volume":"9","author":"Sermet-Gaudelus","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2021.04.011_bib0007","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1378\/chest.103.4.1096","article-title":"Nontuberculous mycobacterial disease in adult cystic fibrosis patients","volume":"103","author":"Aitken","year":"1993","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2007.06.006","article-title":"Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis","volume":"7","author":"Valenza","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2021.04.011_bib0009","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1164\/rccm.200207-679OC","article-title":"Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease","volume":"167","author":"Olivier","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2021.04.011_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1513\/AnnalsATS.201309-310OC","article-title":"Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis","volume":"11","author":"Martiniano","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2165\/00003088-199732020-00004","article-title":"Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes","volume":"32","author":"Peloquin","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jcf.2021.04.011_bib0013","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","article-title":"Drug disposition in cystic fibrosis","volume":"35","author":"Rey","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2021.04.011_bib0014","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","volume":"12","author":"Waters","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jcf.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jcf.2021.04.011_bib0016","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.43.3.568","article-title":"Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids","volume":"43","author":"Peloquin","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/AAC.37.2.314","article-title":"Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension","volume":"37","author":"Nahata","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcf.2021.04.011_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance","volume":"13","author":"de Groot","year":"1987","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jcf.2021.04.011_bib0019","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2165\/00003495-198835050-00004","article-title":"Clinical pharmacology of antibiotics and other drugs in cystic fibrosis","volume":"35","author":"Prandota","year":"1988","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jcf.2021.04.011_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.41.1.184","article-title":"Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis","volume":"41","author":"Touw","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jcf.2021.04.011_bib0021","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","article-title":"Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2021.04.011_bib0022","series-title":"Zithromax (azithromycin)","year":"2013"},{"key":"10.1016\/j.jcf.2021.04.011_bib0023","series-title":"Myambutol (ethambutol)","year":"2007"},{"key":"10.1016\/j.jcf.2021.04.011_bib0024","series-title":"Rifadin (rifampin)","year":"2010"},{"issue":"1","key":"10.1016\/j.jcf.2021.04.011_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0272-5231(05)70357-9","article-title":"Using therapeutic drug monitoring to dose the antimycobacterial drugs","volume":"18","author":"Peloquin","year":"1997","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2021.04.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary mycobacterium avium complex disease treatment","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.04.011_bib0027","series-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","first-page":"59","article-title":"Antituberculosis drugs: pharmacokinetics","author":"Peloquin","year":"1991"},{"issue":"6","key":"10.1016\/j.jcf.2021.04.011_bib0028","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/infdis\/168.6.1559","article-title":"Low serum levels of oral antimycobacterial agents in patients with disseminated mycobacterium avium complex disease","volume":"168","author":"Gordon","year":"1993","journal-title":"J Infect Dis"},{"issue":"25","key":"10.1016\/j.jcf.2021.04.011_bib0029","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199212173272514","article-title":"Malabsorption of antituberculosis medications by a patient with AIDS","volume":"327","author":"Berning","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2021.04.011_bib0030","first-page":"1013","article-title":"Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin","volume":"107","author":"Jenne","year":"1973","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.jcf.2021.04.011_bib0031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1183\/09031936.99.14234799","article-title":"Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease","volume":"14","author":"Gilljam","year":"1999","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2021.04.011_bib0032","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jcf.2021.04.011_bib0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","article-title":"Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease","volume":"186","author":"Koh","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2021.04.011_bib0034","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jcf.2021.04.011_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:45:32Z","timestamp":1761601532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1569199321001211"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.04.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}